Matching articles for "Methylnaltrexone"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Naldemedine (Symproic) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third...
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third oral
peripherally-acting mu-opioid receptor antagonist
(PAMORA) to be approved for this indication; naloxegol
(Movantik) and methylnaltrexone (Relistor) were
approved earlier.
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • September 28, 2015; (Issue 1478)
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain....
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Lubiprostone (Amitiza) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • June 10, 2013; (Issue 1418)
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation...
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation and irritable
bowel syndrome with constipation.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2010; (Issue 92)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Alvimopan (Entereg) for Postoperative Ileus
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 1300)
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug...
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • August 11, 2008; (Issue 1292)
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced...
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.